-
Illumina Announces Fourth Quarter and Fiscal Year 2025 Financial Performance
NASDAQ: $ILMN Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025 Illumina, Inc. today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The company reported solid performance across its core sequencing segments, reflecting continued momentum in both clinical adoption and research applications globally. Fourth Quarter Financial…
-
PTC Therapeutics Announces Date for Fourth Quarter and Full-Year 2025 Financial Results
NASDAQ: $PTCT PTC Therapeutics, a biotechnology company focused on developing innovative treatments for rare diseases, has officially announced the date for the release of its financial performance data for the fourth quarter and the entirety of the 2025 fiscal year. Investors, analysts, and stakeholders can anticipate the official announcement on Thursday, February 19, 2026. This…
-
Insmed to Present Fourth Quarter and Full Year 2025 Financial Results
NASDAQ: $INSM Insmed Incorporated has officially announced the schedule for its upcoming financial results presentation. The company will host a conference call to discuss its financial performance for the fourth quarter and the entirety of the fiscal year 2025. This event is set to take place on Thursday, February 19, 2026. The conference call is…
-
Viatris Announces Q4 and Full-Year 2025 Financial Results Date and Investor Event Schedule
NASDAQ: $VTRS Viatris Inc. has officially announced the schedule for reporting its financial outcomes for the fourth quarter and the entirety of the 2025 fiscal year. This important update for investors and stakeholders is set for release on Thursday, February 26, 2026. Following the release of the comprehensive financial figures, Viatris will host a conference…
-
Amgen’s 2025 Financial Performance: A Review of Fourth Quarter and Full-Year Results
NASDAQ: $AMGN Amgen recently announced its financial results for the fourth quarter and the full year ended December 31, 2025. The company’s performance reflects ongoing strategic initiatives and the impact of its evolving portfolio in the biotechnology sector. For the fourth quarter of 2025, Amgen reported total revenue of approximately $8.2 billion. This figure marks…
-
Riding the Waves: S&P 500 Performance in Election Years
When you think about the stock market, especially the S&P 500, you might wonder how politics plays into the mix. Election years often stir up a whirlwind of emotions, debates, and strategies. But how does this affect one of the most followed stock indices in the U.S.? Let’s dive into how the S&P 500 performs…